A Longitudinal Comparison of Aripiprazole vs. Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

Trial Profile

A Longitudinal Comparison of Aripiprazole vs. Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Aripiprazole (Primary) ; Quetiapine (Primary) ; Risperidone (Primary)
  • Indications Bipolar disorders; Psychotic disorders
  • Focus Pharmacodynamics
  • Acronyms CALM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2016 Status changed from recruiting to completed.
    • 01 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top